These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 38757346)
1. Dual‑regulated oncolytic adenovirus carrying Zhao T; Ye W; Zhang R; Zhu X; Shi Q; Xu X; Chen W; Xu L; Meng Y Mol Med Rep; 2024 Jul; 30(1):. PubMed ID: 38757346 [TBL] [Abstract][Full Text] [Related]
2. Interfering with the expression of EEF1D gene enhances the sensitivity of ovarian cancer cells to cisplatin. Xu Q; Liu Y; Wang S; Wang J; Liu L; Xu Y; Qin Y BMC Cancer; 2022 Jun; 22(1):628. PubMed ID: 35672728 [TBL] [Abstract][Full Text] [Related]
3. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line. Du P; Zhang X; Liu H; Chen L DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922 [TBL] [Abstract][Full Text] [Related]
4. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer. Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334 [TBL] [Abstract][Full Text] [Related]
5. [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum]. Zhang W; Wu FX; Wang Q; Li L Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):286-91. PubMed ID: 22781116 [TBL] [Abstract][Full Text] [Related]
6. ErbB3-Targeting Oncolytic Adenovirus Causes Potent Tumor Suppression by Induction of Apoptosis in Cancer Cells. Jung BK; Kim YJ; Hong J; Chang HG; Yoon AR; Yun CO Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806132 [TBL] [Abstract][Full Text] [Related]
7. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer]. Liu GY; Qu QX; Mi RR; Qi J Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932 [TBL] [Abstract][Full Text] [Related]
8. Rab25 is responsible for phosphoinositide 3-kinase/AKT‑mediated cisplatin resistance in human epithelial ovarian cancer cells. Fan Y; Wang L; Han X; Liu X; Ma H Mol Med Rep; 2015 Mar; 11(3):2173-8. PubMed ID: 25405658 [TBL] [Abstract][Full Text] [Related]
9. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression. Xia A; Li H; Li R; Lu L; Wu X Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933 [TBL] [Abstract][Full Text] [Related]
10. Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin. Ma B; Wang Y; Zhou X; Huang P; Zhang R; Liu T; Cui C; Liu X; Wang Y J Cancer Res Clin Oncol; 2015 Mar; 141(3):419-29. PubMed ID: 25240826 [TBL] [Abstract][Full Text] [Related]
11. Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells. Fang L; Cheng Q; Li W; Liu J; Li L; Xu K; Zheng J Virus Res; 2014 Mar; 181():61-71. PubMed ID: 24463503 [TBL] [Abstract][Full Text] [Related]
12. [Inhibition of Topo II alpha gene expression and reversing of drug resistance in multi-drug resistant epithelial ovarian cancer cells induced by RNA interference in vitro]. He J; Li L; Tang BJ; Zhang W; Li DR; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):686-90. PubMed ID: 20079182 [TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effect of a dual cancer-specific recombinant adenovirus on ovarian cancer cells. Cui Y; Li Y; Li S; Li W; Zhu Y; Wang J; Liu X; Yue Y; Jin N; Li X Exp Cell Res; 2020 Nov; 396(1):112185. PubMed ID: 32828827 [TBL] [Abstract][Full Text] [Related]
14. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity. Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462 [TBL] [Abstract][Full Text] [Related]
15. Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer. Rein DT; Volkmer A; Bauerschmitz G; Beyer IM; Janni W; Fleisch MC; Welter AK; Bauerschlag D; Schöndorf T; Breidenbach M J Cancer Res Clin Oncol; 2012 Apr; 138(4):603-10. PubMed ID: 22209976 [TBL] [Abstract][Full Text] [Related]
16. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. Jiao JW; Wen F Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580 [TBL] [Abstract][Full Text] [Related]
17. RGD-modified oncolytic adenovirus-harboring shPKM2 exhibits a potent cytotoxic effect in pancreatic cancer via autophagy inhibition and apoptosis promotion. Xu Y; Chu L; Yuan S; Yang Y; Yang Y; Xu B; Zhang K; Liu XY; Wang R; Fang L; Chen Z; Liang Z Cell Death Dis; 2017 Jun; 8(6):e2835. PubMed ID: 28569774 [TBL] [Abstract][Full Text] [Related]
18. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway. Ma N; Zhao Y Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818 [TBL] [Abstract][Full Text] [Related]
19. LDR reverses DDP resistance in ovarian cancer cells by affecting ERCC-1, Bcl-2, Survivin and Caspase-3 expressions. Ju X; Yu H; Liang D; Jiang T; Liu Y; Chen L; Dong Q; Liu X Biomed Pharmacother; 2018 Jun; 102():549-554. PubMed ID: 29597088 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth. He G; Lei W; Wang S; Xiao R; Guo K; Xia Y; Zhou X; Zhang K; Liu X; Wang Y J Cancer Res Clin Oncol; 2012 Apr; 138(4):657-70. PubMed ID: 22237452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]